Editact Therapeutics Ltd.

Editact Therapeutics is a biotechnology and pharmaceutical company headquartered in Hong Kong. Dedicated to revolutionizing gene editing technologies and human health, it is pioneering first-in-class “one-for-many” genome editing solutions to familial diseases. Our first drug leads aim to target and treat Familial Alzheimer’s disease (FAD). Editact is committed to addressing unmet medical needs through genome editing, thus offering a new lease on life for patients with inherited and otherwise incurable diseases.